The current study suggests that the visual fields of ROP patients after anti-VEGF therapy may be narrower than those of normal controls at the same age, with significant differences noted at seven of the eight directions tested, as well as the sum across directions. The gene discussed is VEGFA; the disease is retinopathy of prematurity.